|
|
Volumn 36, Issue 7-8, 2002, Pages 1135-1141
|
|
Cost impact of switching histamine2-receptor antagonists to nonprescription status
a
|
|
Author keywords
Drug utilization; H2 receptor antagonists; OTC switch; Pharmacoepidemiology
|
|
Indexed keywords
ALUMINUM MAGNESIUM HYDROXIDE;
ANTACID AGENT;
ANTIULCER AGENT;
ANXIOLYTIC AGENT;
ATTAPULGITE;
BISMUTH SALICYLATE;
CALCIUM CARBONATE;
CAVED S;
CHLORDIAZEPOXIDE PLUS CLIDINIUM BROMIDE;
CIMETIDINE;
DICYCLOVERINE;
DIOVOL;
FAMOTIDINE;
GAVISCON;
GLYCOPYRRONIUM BROMIDE;
HISTAMINE H2 RECEPTOR ANTAGONIST;
LANSOPRAZOLE;
NIZATIDINE;
NON PRESCRIPTION DRUG;
OMEPRAZOLE;
PANTOPRAZOLE;
PHENOBARBITAL;
PIRENZEPINE;
PROKINETIC AGENT;
PROPANTHELINE BROMIDE;
PROTON PUMP INHIBITOR;
RANITIDINE;
SCOPOLAMINE BUTYL BROMIDE;
SPASMOLYTIC AGENT;
SUCRALFATE;
UNINDEXED DRUG;
GASTROINTESTINAL AGENT;
ARTICLE;
CANADA;
CONSUMER;
COST BENEFIT ANALYSIS;
DATA BASE;
DRUG BIOAVAILABILITY;
DRUG COST;
DRUG MARKETING;
DRUG RECEPTOR BINDING;
DRUG UTILIZATION;
GASTROINTESTINAL DISEASE;
HEALTH INSURANCE;
HEALTH SERVICE;
HUMAN;
INTERNATIONAL COOPERATION;
PATIENT SATISFACTION;
PHARMACOEPIDEMIOLOGY;
POPULATION RESEARCH;
PRESCRIPTION;
PRIORITY JOURNAL;
QUALITATIVE DIAGNOSIS;
RECEPTOR BLOCKING;
UNITED KINGDOM;
UNITED STATES;
ECONOMICS;
CANADA;
DRUGS, NON-PRESCRIPTION;
GASTROINTESTINAL AGENTS;
GREAT BRITAIN;
HISTAMINE H2 ANTAGONISTS;
HUMANS;
PHARMACOEPIDEMIOLOGY;
UNITED STATES;
|
|
EID: 0036020152
PISSN: 10600280
EISSN: None
Source Type: Journal
DOI: 10.1345/aph.1A231 Document Type: Article |
|
Times cited : (5)
|
|
References (20)
|
